ILRS Microbial and Biomolecular Interactions

ILRS Microbial and Biomolecular Interactions ILRS Jena is a graduate training program focussing on the microbial and biomolecular interactions underlying microbial communication.

The ILRS is the international graduate training program of the Leibniz Institute for Natural Product Research and Infection Biology – Hans Knöll Institute (HKI) – in cooperation with the Friedrich Schiller University Jena (FSU) and the Max Planck Institute for Chemical Ecology (MPI CE).

Leopoldina: Axel Brakhage re-elected as Chairman and Senator The German Academy of Sciences Leopoldina e. V. , short Leo...
22/01/2024

Leopoldina: Axel Brakhage re-elected as Chairman and Senator
The German Academy of Sciences Leopoldina e. V. , short Leopoldina, has unanimously confirmed the re-election of Prof. Dr. Axel Brakhage as Chairman. Axel Brakhage thus remains Chairman and Senator of Section 13 - Microbiology and Immunology, of which he has been a member of the Leopoldina since 2020. His second term of office begins in March 2024 and will last 4 years.

The German Academy of Sciences Leopoldina e. V. , short Leopoldina, has unanimously confirmed the re-election of P…

Inernational meeting From December 12-14, a delegation from the Chinese-German Center for Science Promotion (CDZ) visite...
03/01/2024

Inernational meeting
From December 12-14, a delegation from the Chinese-German Center for Science Promotion (CDZ) visited the Leibniz-HKI in Jena. The CDZ is a joint research funding organization of the German Research Foundation (DFG) and the National Natural Science Foundation of China (NSFC) based in Beijing. Representatives from Beijing and from the DFG's head office were present. The reason for the visit was the meeting of the Joint Commission of the DFG and NSFC, which is chaired by Axel Brakhage, Vice President of the DFG. The first face-to-face meeting since the outbreak of the COVID-19 pandemic was characterized by lively communication and a successful exchange of knowledge, and points the way for continued good cooperation. The delegation was able to get to know our research work during a tour of the institute. The meeting with Chinese researchers on site supported communication and showed the advantages and possibilities of international cooperation.

From December 12-14, a delegation from the Chinese-German Center for Science Promotion (CDZ) visited the Leibniz-H…

Shanghai Archaeology Forum honors Christina Warinner with 2023 Research Award
14/12/2023

Shanghai Archaeology Forum honors Christina Warinner with 2023 Research Award

Christina Warinner, head of the associated research group archaeogenetics at the Leibniz-HKI, has been awarded a prestigious Research Award by the Shanghai Archaeology Forum (SAF) in recognition of her contributions to the study of ancient human microbiomes. The Research Award recognizes excellence....

Award for high-resolution microscopy method An interdisciplinary cooperation between several research institutes was hon...
21/11/2023

Award for high-resolution microscopy method
An interdisciplinary cooperation between several research institutes was honored with the Beutenberg Campus Jena e. V. Science Award on 15.11.2023.

An interdisciplinary cooperation between several research institutes was honored with the Beutenberg Campus Jena e…

Medicine for all: Marie von Lilienfeld-Toal appointed to professorship Since July 1 of this year, Marie von Lilienfeld-T...
01/11/2023

Medicine for all: Marie von Lilienfeld-Toal appointed to professorship
Since July 1 of this year, Marie von Lilienfeld-Toal has been Professor of "Health Services Research in Oncology" at the Ruhr University Bochum (RUB). The chair will soon be renamed "Diversity Medicine", and von Lilienfeld-Toal is also establishing the first German Institute for Diversity Medicine.

Marie von Lilienfeld-Toal has been associated with the Leibniz-HKI with her Infections in Hematology/Oncology group since her appointment at Friedrich Schiller University Jena in 2013, and she also conducted research at the University Hospital Jena. Her team studies invasive fungal infections in particular, which are especially dangerous for cancer patients. For example, it was involved in the development of an "aspergillosis-on-chip" model that investigates the infection mechanisms of the fungus Aspergillus fumigatus in the lungs.

As a physician, von Lilienfeld-Toal is also concerned with side effects of therapies - which are not the same for everyone. "My goal is a medicine that takes maximum account of the context in which a person finds himself or herself and thereby contributes to health equality for all population groups," she is quoted as saying in an article published by the RUB.

The new Institute for Diversity Medicine addresses these contexts, which have often been ignored in medicine, resulting in poorer care for certain populations. Because many medical studies have been conducted only on men from Europe or America, diseases in other populations - whether of a different gender, skin color or culture - are often less well recognized or treated. For example, heart attacks in women are often not diagnosed in a timely manner and skin diseases on darker skin are overlooked.

One of the aims of the Institute for Diversity Medicine is to improve the data situation in Germany on the consequences of this unequal treatment. Currently, there are mainly studies from the U.S. that show worse treatment of marginalized populations.

Marie von Lilienfeld-Toal will remain closely associated with Leibniz-HKI through her participation in the DFG Collaborative Research Center FungiNet (Transregio).

Since July 1 of this year, Marie von Lilienfeld-Toal has been Professor of "Health Services Research in Oncolo…

Research prizes for the Leibniz-HKI This fall, a veritable shower of prizes fell on the scientists of the Leibniz-HKI. S...
20/10/2023

Research prizes for the Leibniz-HKI
This fall, a veritable shower of prizes fell on the scientists of the Leibniz-HKI. Several prizes were awarded at this year's meetings of microbiological societies.

At the annual meeting of the German Society for Hygiene and Microbiology (DGHM), in addition to Mark Gresnigt, who received the Young Investigator Award, the poster on the topic of what influence the host protein albumin has on vulvovaginal candidiasis was also awarded. The poster was a team effort: first author is Sophie Austermeier, PhD student in the Department of Microbial Pathogenicity Mechanisms, the presentation at the meeting was made by Sophia Hitzler, PhD student in the Junior Research Group Adaptive Pathogenicity Strategies.

A doctoral award was presented to Shuaibing Zhang from the Department of Paleobiotechnology at the annual meeting of the Association for General and Applied Microbiology (VAAM). His work focuses on the ecological role of natural products in microbial hunter-prey relationships.

But it was not only at the annual meetings of the DGHM and the VAAM that prizes went to Leibniz-HKI scientists.

This fall, a veritable shower of prizes fell on the scientists of the Leibniz-HKI. Several prizes were awarded at …

Mark Gresnigt received DGHM-Förderpreis 2023 One of this year's funding awards of the German Society for Hygiene and Mic...
04/10/2023

Mark Gresnigt received DGHM-Förderpreis 2023
One of this year's funding awards of the German Society for Hygiene and Microbiology (DGHM) goes to Mark Gresnigt, head of the Emmy Noether Junior Research Group Adaptive Pathogenicity Strategies at Leibniz-HKI.

On the occasion of the annual meeting of the DGHM in Lübeck at the end of September, special achievements in the field of infection and drug research were honored. Mark Gresnigt, group leader at Leibniz-HKI received one of this year's funding awards. Gresnigt researches strategies of Candida species, especially Candida albicans, to adapt to changing host conditions in order to persist in the human microbiota. These may include, for example, increased temperature during infection or host defense molecules. Certain yeasts of the Candida genus that colonize the human body are normally harmless. However, under certain conditions, they can become pathogens with the potential to cause both superficial and fatal infections. They are therefore referred to as opportunistic pathogens. The Adaptive Pathogenicity Strategies group, led by Gresnigt, is particularly interested in the underlying molecular mechanisms that induce such adaptations and the proteins that are sensed by the fungus.

In his PhD thesis, Gresnigt focused on pattern recognition and specific signaling pathways involved in host defense against the opportunistic pathogenic mold Aspergillus fumigatus. As a postdoctoral fellow, he studied the metabolic changes that occur in circulating monocytes when exposed to endotoxin from the intestinal bacterium Escherichia coli. This experimental model mimics human sepsis. Gresnigt was thus able to show that the drastic systemic immune activation by endotoxemia causes monocytes to lose their metabolic plasticity. As a result, they also forfeit their ability to trigger cytokine responses, release reactive oxygen species, and clear the opportunistic pathogenic fungus Candida albicans.
In 2018, Mark Gresnigt then moved to the Leibniz-HKI in Jena with an Alexander von Humboldt Postdoctoral Fellowship.

Together with the Department of Microbial Pathogenicity Mechanisms, he received the Research Promotion Award of the German-speaking Mycological Society in 2021 and the medac Research Award in 2022. Four of his 69 scientific publications to date have already been selected as paper of the month by the DGHM Board.
The second DGHM Research Promotion Prize was awarded this year to Katharina Schauffler, Professor of Epidemiology and Ecology of Antimicrobial Resistance at the Helmholtz Institute for One Health (University of Greifswald) and Junior Research Group Leader at the Institute of Pharmacy at the University of Greifswald.

One of this year's funding awards of the German Society for Hygiene and Microbiology (DGHM) goes to Mark Gresn…

Productive against all expectations Contrary to previous theories, Early diverging fungi (EDF) could also be producers o...
26/09/2023

Productive against all expectations
Contrary to previous theories, Early diverging fungi (EDF) could also be producers of important natural products. One division of EDF contradicts this common dogma by possessing a secondary metabolism. Via a two-step biosynthesis, the fungi produce lindolin, a natural substance that is effective against pathogens of fruit rot. This was discovered by researchers of the Leibniz-HKI and the Friedrich-Schiller-University during the investigation of a representative of the Zoopagomycota.

Early diverging fungi arose early in the course of evolution and branched off in the phylogenetic tree. While the higher fungi are already well studied and about 40,000 natural compounds are known, only up to 500 substances have been discovered so far in EDF. The preliminary work on which the research team led by Markus Greßler of the Pharmaceutical Microbiology Research Group is based dates back a good 50 years. One reason for the stepmotherly treatment of these fungi is the assumption, still valid today, that they do not possess their own secondary metabolism that produces interesting substances.

A neglect unjustly as it seems. While studying Linderina pennispora, a fungus from the Zoopagomycota division, the researchers discovered that it independently produces certain indole alkaloids. "We named the substance Lindolin, combining the name of the fungus and the basic structure of the active ingredient," Greßler explains. The independent production is significant because it is often not the EDF themselves that produce a natural substance, but bacterial endosymbionts living within them.

Contrary to previous theories, Early diverging fungi (EDF) could also be producers of important natural products. …

INCATE marks two-year anniversary INCATE (the INCubator for Antibacterial Therapies in Europe) has successfully reached ...
13/09/2023

INCATE marks two-year anniversary
INCATE (the INCubator for Antibacterial Therapies in Europe) has successfully reached its two-year milestone, boasting an impressive array of achievements. With a direct contact to over 180 startups and initiatives, a thriving portfolio of 24 ventures (and more in the pipeline), and valuable partnerships that have propelled the project forward, INCATE stands as a beacon of progress in its field. The Leibniz-HKI is one of INCATES founding members.

Launched in August 2021, INCATE has been committed to its mission to bolster early stage innovators in the Antimicrobial Resistance field. By providing advice, community, and non-dilutive funding, the project empowers entrepreneurs to construct compelling business propositions and compile the evidence requisite to attract investors.

INCATE was contacted by over 180 start-ups and projects, gathering more than 80 applications. The establishment of a robust pipeline for new ventures has been a hallmark accomplishment, along with furnishing essential support to 24 ventures at Stage I. The current portfolio of Stage I ventures comes from 15 countries so far, with over half not founded as companies when they first contacted INCATE. The technologies selected include traditional direct acting small molecules and peptides but also phages, anti-virulence and other technologies. Notably, one of these ventures moved forward to Stage II in January 2023. At present, the landscape includes some INCATE ventures that have achieved the coveted “investable stage” status, successfully securing equity investment and forging impactful collaborations. This includes Smartbax, Invitris. There will be further Stage II Investments at the end of 2023 and during 2024. INCATE earned the distinction of a “unique role” in the European Commission’s report on medical countermeasures and played a vital role in the WHO pre-clinical pipeline report in 2023.

The year 2023 also marks the beginning of another major milestone, as INCATE's supporting partner, the Leibniz Association, has invested €1 million in the project, which has allowed the team to grow and focus even more on supporting innovators in this fight against silent pandemics. The Leibniz-HKI is significantly represented in the management team of INCATE with three employees.

INCATE (the INCubator for Antibacterial Therapies in Europe) has successfully reached its two-year milestone, boas…

New approach in the treatment of non-alcoholic fatty liver disease (NAFLD) The prebiotic resistant starch could play an ...
06/09/2023

New approach in the treatment of non-alcoholic fatty liver disease (NAFLD)
The prebiotic resistant starch could play an important role in the treatment of non-alcoholic fatty liver disease (NAFLD) in the future. Initial indications suggest that a specially adapted diet with resistant starch not only positively influences the intestinal microbiome but also leads to an alleviation of the disease. This is what an international research team from the “Balance of the Microverse” Cluster of Excellence at the University of Jena, Shanghai Sixth People's Hospital Affiliated to Shanghai Jiao Tong University School of Medicine (SSPH-SJTUSM) and the Leibniz Institute for Natural Product Research and Infection Biology (Leibniz-HKI) found in a recent study.

Previous studies suggest that fatty liver disease that is not caused by excessive alcohol consumption is closely related to the gut microbiome, and microbiota-directed foods could be an effective non-pharmacological intervention to deal with NAFLD. Against this background, the researchers conducted a clinical nutritional study with patients affected by the disease. The results have now been published in the current issue of the research journal Cell Metabolism.

"We found out that the participants in the study benefited from a resistant starch diet, as the accumulation of fat in the diseased liver was reduced. Furthermore, we observed an increase in certain types of bacteria in the gut of the participants; these bacteria positively influenced fat reduction and transport in the liver. In addition, reduced NAFLD and inflammation biomarkers indicate an alleviation of liver damage," summarized study leader Gianni Panagiotou, Professor for Microbiome Dynamics at the Cluster of Excellence "Balance of the Microverse" at the University of Jena.

Resistant starch belongs to the dietary fibres and is found, for example, in bread, pasta, and legumes. It consists of indigestible fibres, and thus, has a prebiotic effect in the gut. “We found that the number of beneficial bacteria increases when resistant starch is metabolized by microorganisms in the colon. At the same time, the number of harmful bacteria decreases", explains first author Yueqiong Ni. "This leads to a more balanced gut microbiome and has a positive impact on health."

The team led by Gianni Panagiotou, Weiping Jia, Yueqiong Ni, and Huating Li examined serum and f***l samples from 200 participants over a period of four months. They found that the level of Bacteroides stercoris, in particular, increases significantly the more severe the disease is. “In our study, we found Bacteroides stercoris occurred in less amount in test persons after eating 40 grams of resistant starch per day”, says co-corresponding author Huating Li. The researchers conclude that it is advisable to consume a fist-sized amount of "healthy" carbohydrates naturally containing resistant starch, such as wholegrain cereals, legumes, green bananas, and starchy vegetables like potatoes at every meal to alleviate fatty liver.

Currently, about 30 percent of the world's population suffers from non-alcoholic fatty liver disease. Thus, the disease is classified as an epidemic by the World Health Organisation (WHO). The metabolic disorder can also aggravate diseases such as type 2 diabetes or cardiovascular diseases. However, for affected patients, no drug therapy has yet been approved. In order to make concrete nutritional recommendations, further and longer-term studies are necessary, according to the "American Association for the Study of Liver Diseases".

The study was supported by the German Research Foundation (DFG) within the framework of the Cluster of Excellence Balance of the Microverse and by the Leibniz Association.

The prebiotic resistant starch could play an important role in the treatment of non-alcoholic fatty liver disease …

Cofactor W₃: Gerald Lackner appointed to professorship As of September 1, Gerald Lackner is Professor of Biochemistry of...
29/08/2023

Cofactor W₃: Gerald Lackner appointed to professorship
As of September 1, Gerald Lackner is Professor of Biochemistry of Microorganisms at the University of Bayreuth. His chair is located in the new Faculty of Life Sciences: Food, Nutrition and Health at the Kulmbach Campus.

Gerald Lackner has a long history with Jena and the Leibniz-HKI. He studied biochemistry at the University of Jena and subsequently conducted his doctoral research in the department of Biomolecular Chemistry of Christian Hertweck at Leibniz-HKI. After postdoctoral positions with Dirk Hoffmeister at the University of Jena and as a Feodor Lynen Research Fellow at ETH Zurich, Lackner returned to Leibniz-HKI and established the Synthetic Microbiology Junior Research Group.

Lackner's group studies so-called cryptic biosynthetic gene clusters, i.e. gene clusters whose products are (still) unknown. To correlate these gene clusters with their associated metabolites, the group combines functional genomics with comparative metabolomics.

Lackner and his team achieved decisive breakthroughs, particularly in the field of cofactors from mycobacteria. They focused in particular on the coenzyme F420 and on mycofactocin. In addition to elucidating the biosynthesis and physiological function of these substances, they also looked at how they can be produced on a larger scale and thus made biotechnologically viable.

At the University of Bayreuth, Gerald Lackner will help establish the new Faculty of Life Sciences: Food, Nutrition and Health. "The development of the new campus of the University of Bayreuth in Kulmbach is an exciting project that will bring important impulses to the Upper Franconia region. I am pleased to be able to support the location with research and teaching in the field of food microbiology and biotechnology," Lackner said.

The Synthetic Microbiology Group at Leibniz-HKI will continue to complete ongoing projects until spring 2024.

As of September 1, Gerald Lackner is Professor of Biochemistry of Microorganisms at the University of Bayreuth. Hi…

Small differences with a big effect How do our genes determine the immune response to pathogens? That depends on small d...
13/06/2023

Small differences with a big effect
How do our genes determine the immune response to pathogens? That depends on small differences in the genome. The situation is complex, as a new study shows.

How do our genes determine the immune response to pathogens? That depends on small differences in the genome. The …

Adresse

BeutenbergStr. 11a
Jena
07745

Benachrichtigungen

Lassen Sie sich von uns eine E-Mail senden und seien Sie der erste der Neuigkeiten und Aktionen von ILRS Microbial and Biomolecular Interactions erfährt. Ihre E-Mail-Adresse wird nicht für andere Zwecke verwendet und Sie können sich jederzeit abmelden.

Die Organisation Kontaktieren

Nachricht an ILRS Microbial and Biomolecular Interactions senden:

Teilen